Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

75%

3 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
3(100.0%)
3Total
Phase 4(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06617754Active Not Recruiting

International Severe CRSwNP Registry 2024-2028

Role: lead

NCT05598814Phase 4Active Not Recruiting

Mepolizumab to CRSwNP Through 12 Months - Randomised to FESS and Non-FESS Within the First 2 Weeks

Role: lead

NCT05749523Phase 4Withdrawn

The Influence of Exercise and Hydration to the Pharmacological Response to Inhaled Terbutalin and Salbutamol in Men

Role: lead

NCT02233231Phase 4Completed

Smoking Young Asthmatics: Change of Inflammation During Tobacco Cessation and Steroid Treatment

Role: lead

All 4 trials loaded